TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
This transaction fundamentally strengthens Scinai's CDMO platform
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
Subscribe To Our Newsletter & Stay Updated
